P Marlton

Sort by:

The genomic landscape of hypodiploid acute lymphoblastic leukemia

Linda Holmfeldt, Lei Wei, +60 authors Charles G Mullighan
Nature Genetics
2013

The genetic basis of hypodiploid acute lymphoblastic leukemia (ALL), a subtype of ALL characterized by aneuploidy and poor outcome, is unknown. Genomic profiling of 124 hypodiploid ALL cases,… (More)

Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.

Kirsten J Fischer, Jasmin Bahlo, +21 authors Michael J Hallek
Blood
2016

Despite promising results with targeted drugs, chemoimmunotherapy with fludarabine, cyclophosphamide (FC), and rituximab (R) remains the standard therapy for fit patients with untreated chronic… (More)

Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review.

Glen A. Kennedy, Siok-Keen Tey, +5 authors Devinder S Gill
British journal of haematology
2002

Re-treatment with rituximab for B-cell non-Hodgkin's lymphoma (NHL) relapsing after previous rituximab therapy has recently been shown to be clinically efficacious. Although the mechanism of… (More)

Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma.

Franck Morschhauser, P Marlton, +9 authors Myriam Mendila
Annals of oncology : official journal of the…
2010

BACKGROUND Ocrelizumab is a humanized anti-CD20 antibody with increased antibody-dependent cellular cytotoxicity compared with rituximab. This phase I/II study evaluated its safety and efficacy in… (More)

Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma.

Maher K Gandhi, Eleanore Lambley, +13 authors Rajiv Khanna
Clinical cancer research : an official journal of…
2006

PURPOSE Latent Epstein-Barr virus (EBV) genomes are found in the malignant cells of approximately one-third of Hodgkin's lymphoma (HL) cases. Detection and quantitation of EBV viral DNA could… (More)

Integrative genomic profiling reveals conserved genetic mechanisms for tumorigenesis in common entities of non-Hodgkin's lymphoma.

Michael R Green, Carlos Aya-Bonilla, +5 authors Lyn R Griffiths
Genes, chromosomes & cancer
2011

Recent developments in genomic technologies have resulted in increased understanding of pathogenic mechanisms and emphasized the importance of central survival pathways. Here, we use a novel… (More)

WT1 expression as a marker of minimal residual disease predicts outcome in acute myeloid leukemia when measured post-consolidation.

James X. Gray, Lyle McMillen, +6 authors P Marlton
Leukemia research
2012

WT1 levels may be a useful predictor of leukemia free survival (LFS) following treatment of acute myeloid leukemia (AML). We report a retrospective study in which levels of WT1 expression from… (More)

Type C Niemann-Pick disease.

Glen A. Kennedy, Rachel S. Cobcroft, P Marlton, P. A. Silburn, Matt Walsh, Raymond G. Boyle
British journal of haematology
2000

The KIR2DS2/DL2 genotype is associated with adult persistent/chronic and relapsed immune thrombocytopenia independently of FCGR3a-158 polymorphisms.

Jamie P. Nourse, R. K. Lea, +7 authors Maher K Gandhi
Blood coagulation & fibrinolysis : an…
2012

Adult immune thrombocytopenia (ITP) is a heterogeneous disease and its immunobiology is incompletely understood. Establishing associations between candidate genes and ITP susceptibility may provide… (More)

Treatment of acute promyelocytic leukaemia in the Jehovah’s Witness population

Colm Keane, Peter N. Mollee, P Marlton, Devinder S Gill
Annals of Hematology
2010

Filter Results:

Publication Year

Publication Type

Co-author

Journals and Conferences